Globus Medical has announced an agreement to acquire Nevro Corp. in an all-cash transaction valued at approximately $250 million. Under the terms of the deal, Globus Medical will purchase all shares of Nevro for $5.85 per share, a price representing a 27 percent premium over Nevro’s 90-day volume-weighted average price. The Boards of Directors of both companies have unanimously approved the acquisition, which is expected to close by late Q2 2025, pending shareholder and regulatory approvals. Globus Medical aims to expand into new markets and enhance its neuromodulation and implant technology portfolio. Nevro will benefit from Globus Medical’s operational capabilities and global infrastructure, allowing it to reach more patients with its chronic pain treatment solutions.
Following the acquisition, Globus Medical anticipates 2025 net sales between $2.80 billion and $2.90 billion, with the transaction expected to boost earnings in the second year. Dan Scavilla, President and CEO of Globus Medical, said, “This transaction furthers our mission to become the preeminent musculoskeletal technology company in the world by enabling us to expand into new markets for future growth, while gaining access to world-class, differentiated technologies that can provide significant benefit in neuromodulation, enabling technologies, and future implant solutions.” Morgan Stanley & Co. and Wyrick Robbins Yates & Ponton are advising Globus Medical, while BofA Securities and Latham & Watkins are representing Nevro.
